| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Risuteganib | ALG-1001; AM011; AM-011(Allegro Ophthalmics) | Phase 1 Clinical | Allegro Ophthalmics Llc | Diabetic macular oedema; Diabetic Retinopathy; Geographic Atrophy; Macular Degeneration | Details |
| Pegylated recombinant human endostatin (Tsinghua University) | M-2ES; CRB-0401 | Phase 1 Clinical | Beijing Proji Pharmaceutical Technology Co Ltd, Beijing Protgen Biotechnology Development Co Ltd, Tsinghua University | Carcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details |
| VAX-014 | VAX-014 | Phase 1 Clinical | Vaxiion Therapeutics Llc | Solid tumours | Details |
| Integrin α5β1 therapy (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Cardiovascular Diseases | Details |
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant human endostatin (Simcere) | YH-16 | Approved | Jiangsu Simcere Pharmaceutical Co Ltd | Endostar, 恩度, Endu | Mainland China | Carcinoma, Non-Small-Cell Lung | Shandong Xiansheng Zaiming Biopharmaceutical Co Ltd | 2005-09-12 | Ascites; Brain metastases; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Nasopharyngeal Carcinoma; Osteosarcoma; Pleural Effusion, Malignant | Details |